Home » Stocks » ISR

IsoRay, Inc. (ISR)

Stock Price: $1.98 USD 0.07 (3.66%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 170.10M
Revenue (ttm) 9.75M
Net Income (ttm) -3.35M
Shares Out 68.90M
EPS (ttm) -0.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $1.98
Previous Close $1.91
Change ($) 0.07
Change (%) 3.66%
Day's Open 2.01
Day's Range 1.77 - 2.09
Day's Volume 19,144,954
52-Week Range 0.36 - 2.09

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

RICHLAND, Wash., Jan. 07, 2021 (GLOBE NEWSWIRE) --  Isoray, Inc. (NYSE American: ISR), a medical technology company and seed brachytherapy innovator powering expanding treatment options throug...

Benzinga - 1 week ago

Alkido Pharma (NASDAQ: AIKI) shares are trading higher after the company announced it executed a Patent License Agreement for technology that covers the use of psilocybin for cancer applicatio...

Other stocks mentioned: CHNG, AIKI
GlobeNewsWire - 1 month ago

Studies Demonstrate Impact of Proprietary Isotope on Prostate and Brain Cancers At World's Premier Radiation Oncology Society Studies Demonstrate Impact of Proprietary Isotope on Prostate and ...

Seeking Alpha - 2 months ago

IsoRay, Inc. (ISR) CEO Lori Woods on Q1 2021 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and -21.32%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 2 months ago

Revenue Increased 3% Year-Over-Year

Zacks Investment Research - 2 months ago

IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 2 months ago

Conference Call is Tuesday, November 10, 2020 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Tuesday, November 10, 2020 at 4:30 p.m. ET/1:30 p.m. PT

GlobeNewsWire - 2 months ago

RICHLAND, Wash., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR) (“Isoray” or the “Company”), a medical technology company and innovator in seed brachytherapy powering expa...

Seeking Alpha - 3 months ago

IsoRay, Inc. (ISR) CEO Lori Woods on Q4 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

IsoRay (ISR) delivered earnings and revenue surprises of -100.00% and -17.73%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 3 months ago

Record Full Year Revenue and Gross Profit Full Year Revenue Increased 32% Year-Over-Year Record Full Year Revenue and Gross Profit Full Year Revenue Increased 32% Year-Over-Year

GlobeNewsWire - 3 months ago

RICHLAND, Wash., Sept. 16, 2020 (GLOBE NEWSWIRE) --   Isoray, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment option...

GlobeNewsWire - 4 months ago

Conference Call is Thursday, September 17, 2020, at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Thursday, September 17, 2020, at 4:30 p.m. ET/1:30 p.m. PT

GlobeNewsWire - 6 months ago

Trial Will Evaluate Use of Pembrolizumab, Known as Keytruda®*, With Cesium-131 and Surgical Resection Trial Will Evaluate Use of Pembrolizumab, Known as Keytruda®*, With Cesium-131 and Surgica...

Zacks Investment Research - 7 months ago

IsoRay (ISR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GlobeNewsWire - 7 months ago

RICHLAND, Wash., June 02, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE American: ISR) today announced that the results of a new ten year study show positive outcomes for low-risk and inter...

Seeking Alpha - 8 months ago

IsoRay, Inc. (ISR) CEO Lori Woods on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and 4.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 8 months ago

Record Revenue and Gross Profit Revenue Increased 50% Year-Over-Year Record Revenue and Gross Profit Revenue Increased 50% Year-Over-Year

GlobeNewsWire - 8 months ago

RICHLAND, Wash., May 12, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE American: ISR) today announced that the Centers for Medicare and Medicaid Services (CMS) has approved 64 ICD-10-PCS bil...

Zacks Investment Research - 9 months ago

IsoRay (ISR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Seeking Alpha - 10 months ago

IsoRay Is Set For Further Growth

Zacks Investment Research - 11 months ago

IsoRay (ISR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Seeking Alpha - 11 months ago

IsoRay, Inc. (ISR) CEO Lori Woods on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and -7.70%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 11 months ago

IsoRay: Turned Around And Growing

GlobeNewsWire - 11 months ago

Bundled Treatment Program Provides New Opportunities For Treating Physicians and Patients Facing Limited Options Bundled Treatment Program Provides New Opportunities For Treating Physicians an...

Seeking Alpha - 1 year ago

IsoRay Likely Has Further To Rise

Zacks Investment Research - 1 year ago

IsoRay (ISR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Seeking Alpha - 1 year ago

IsoRay, Inc. (ISR) CEO Lori Woods on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

IsoRay (ISR) delivered earnings and revenue surprises of 50.00% and 4.05%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

Isoray, Inc. (NYSE AMERICAN: ISR) announced today that it will demonstrate its latest products at the American Brachytherapy Society’s (ABS) annual prostate brachytherapy workshop. The worksh...

Seeking Alpha - 1 year ago

IsoRay, Inc. (ISR) CEO Lori Woods on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and 5.71%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 1 year ago

Record Full Year Revenue Driven by 27% Growth in the Company’s Core Prostate Brachytherapy

GlobeNewsWire - 1 year ago

Overall Ten-Year Biochemical Success Rate for Entire Group Was 96.2%Largest and Longest Followed Series of Cesium-131 Treated Patients Reported to Date

GlobeNewsWire - 1 year ago

RICHLAND, WASHINGTON, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment opti...

Seeking Alpha - 1 year ago

IsoRay, Inc. (ISR) CEO Lori Woods on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

About ISR

Isoray, through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily... [Read more...]

Industry
Medical Instruments & Supplies
Founded
1983
CEO
Lori Woods
Employees
53
Stock Exchange
NYSEAMERICAN
Ticker Symbol
ISR
Full Company Profile

Financial Performance

In 2020, IsoRay's revenue was $9.68 million, an increase of 32.35% compared to the previous year's $7.31 million. Losses were -$3.45 million, -33.01% less than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for IsoRay stock is "Strong Buy." The 12-month stock price forecast is 1.45, which is a decrease of -26.77% from the latest price.

Price Target
$1.45
(-26.77% downside)
Analyst Consensus: Strong Buy